FDA Inspection 1010922 — Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. — FEI 3005209462

The FDA completed an inspection of Supernus Pharmaceuticals, Inc. on Feb 3, 2017 in Rockville, MD. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Feb 3, 2017
Fiscal Year
2017
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Rockville, MD (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
683121 CFR 314.80(c)(2)Late submission of quarterly safety reports

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.